A. T. McGuire

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals

This study shows that CD4bs immunogens can elicit potent, broad anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

Structural basis for broad coronavirus neutralization

This study identifies a monoclonal antibody that broadly neutralizes multiple beta-coronaviruses by targeting a conserved epitope, providing a structural basis for designing pan-coronavirus vaccines.

Designed proteins assemble antibodies into modular nanocages

The paper designs modular nanocages that assemble antibodies into precise geometries, enhancing signaling and neutralization compared to free antibodies.

Protective Antibodies Against Human Parainfluenza Virus Type 3 (HPIV3) Infection

The paper identifies a monoclonal antibody, PI3-E12, that neutralizes HPIV3 and provides protection in cotton rats, showing potential for clinical use in both immunocompetent and immunocompromised individuals.

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

The paper determines the X-ray crystal structure of a potent SARS-CoV-2 neutralizing antibody, CV30, in complex with the RBD, showing its epitope overlaps with ACE2 binding site.

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

This study characterizes neutralizing antibodies from a SARS-CoV-2 infected individual, finding that most antibodies are non-neutralizing and target epitopes outside the RBD, while two potent neutralizers bind the RBD with minimal mutation.

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

This study characterizes the structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, showing its receptor-binding properties, furin cleavage site, and potential for cross-neutralizing antibodies.

Antigen-specific humoral immune responses by CRISPR/Cas9-edited B cells

CRISPR/Cas9-edited B cells produce broadly neutralizing antibodies against HIV-1 and elicit protective immune responses in vivo.